Table of Contents Show
The Indian biotech landscape has witnessed yet another significant milestone as ELMED Life Sciences, a Hyderabad headquartered startup, successfully closed a $2.7 million (approximately ₹25 crore) Series A funding round. The investment came from the NABARD-backed AgriSURE Fund, managed by NABVENTURES, signalling growing institutional confidence in microbiome-driven agricultural and health solutions.
A Company Built on Microbiome Science
Established by founder Pruthivin Reddy Madduri and co-founder Nikhil Konkathi, ELMED Life Sciences has carved a distinct position in the biotechnology space by developing probiotic and microbiome-based biological products. The company’s portfolio spans four core verticals animal health, agriculture, aquaculture, and human health addressing the rising global need for sustainable, antibiotic free alternatives across industries.
Its product range serves a diverse clientele, including poultry farmers, dairy operators, livestock managers, aquaculture enterprises, and soil health practitioners. Operating on a B2B model, ELMED serves enterprise clients across multiple sectors, establishing itself as a trusted partner in productivity and sustainability.
Also Read: Fashion Technology Startup Thread Factory Raises Rs 1.5 Crore in Pre-Seed Round Led by AJVC
Expanding Footprint, Deepening Impact
With operations already reaching over 18 countries, ELMED Life Sciences is not a nascent player finding its footing — it is a growth stage company ready to scale. The Series A capital will be strategically channelled into three key areas: strengthening manufacturing capacity at its Hyderabad facility, intensifying research and development efforts, and broadening distribution networks across tier 2 and tier 3 markets in India.
The domestic expansion into smaller markets reflects a deliberate and timely strategy. As awareness of sustainable farming practices grows beyond metropolitan centres, demand for biological and probiotic solutions is rising steadily across tier 2 and tier 3 regions.
Tapping Into a Global Shift
Internationally, demand for antibiotic free and sustainable solutions is increasing across global markets, presenting a significant commercial opportunity for companies like ELMED. This aligns well with the company’s existing international presence and its focus on microbiome based alternatives.
By positioning its portfolio at the intersection of productivity and sustainability, ELMED Life Sciences is well placed to capture this demand. The backing of NABVENTURES’ AgriSURE Fund further lends credibility to its growth trajectory, reinforcing that microbiome based innovation is no longer a niche pursuit — it is fast becoming an industry imperative.
Also Read: Fast&Up Parent Fullife Healthcare Closes Rs 300 Crore Series D Funding Round Led by Elev8
